Market Newsdesk

Better Therapeutics Highlights Recent Progress and Updates Outlook Through 2022

Pivotal trial of BT-001 in type 2 diabetes expected to be fully enrolled in Q4 2021, with primary endpoint readout in Q1 2022; de novo submission to FDA requesting marketing authorization planned following completion of trial

 Clinical development of BT-002 and BT-003 in hypertension and hyperlipidemia on track; pivotal studies expected to commence in 2022

Early clinical discovery in non-alcoholic fatty liver disease (NAFLD) expected to enroll first patient in Q1 2022

Real-world evidence study evaluating the long-term effectiveness and healthcare cost impact of BT-001 to enroll first patient in Q4 2021; two study partners (Colorado Prevention Center and Catalyst Health Network) announced and one more anticipated

New patent filing covering inventions in nutritional cognitive behavior therapy and the use of AI to guide treatment expands intellectual property portfolio

Up to $150M in cash from financing activities including merger with Mountain Crest Acquisition Corp II, a special purpose acquisition company or “SPAC”; a fully committed $50M PIPE; and a $50M debt facility provide an operating runway into 2023

SAN FRANCISCO–(BUSINESS WIRE)–Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today provided an update on recent progress since announcing its intention to merge with Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) (“Mountain Crest II”). The merger and concurrent PIPE and debt financings are expected to close in October.

“I’m pleased with the progress we’ve made since announcing our plans to become a public company through a merger with Mountain Crest II,” said Kevin Appelbaum, co-founder and chief executive officer of Better Therapeutics. “We’ve advanced our clinical pipeline in type 2 diabetes, hypertension, hyperlipidemia and non-alcoholic fatty liver disease (NAFLD). Our potentially pivotal study of BT-001, a PDT for the treatment of type 2 diabetes, is approaching full enrollment, and a real-world evidence study of BT-001 is about to begin enrolling. We expect the data generated from the pivotal study will form the basis of our planned de novo submission to FDA requesting marketing authorization of BT-001, and data from the real-world evidence study, if positive, will provide compelling evidence of clinical and economic impact to support reimbursement coverage. We’ve added a fourth patent family to our intellectual property portfolio, and, through the SPAC, PIPE and debt financings, we will be well funded into 2023, as we progress towards the commercial launch of our first PDT in diabetes and advance our pipeline across multiple cardiometabolic diseases.”

The Better Therapeutics platform blends clinical, behavioral and psychological inputs into a series of cognitive behavioral therapy lessons and skill-building modules designed to shift neural pathways of the brain and treat the disease at its source through behavior change. Following FDA marketing authorization or clearance, it is anticipated that primary care providers will prescribe, and insurers will reimburse, Better Therapeutics’ PDTs much like they would a traditional medication.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDTs is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ PDTs are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information, visit: bettertx.com.

About Mountain Crest Acquisition Corp. II

Mountain Crest Acquisition Corp. II is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Mountain Crest II’s efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the company intends to focus on operating businesses in North America.

Additional Information

On April 6, 2021, Better Therapeutics entered into a definitive merger agreement with Mountain Crest II , a special purpose acquisition company for a proposed business combination.

In connection with the proposed business combination between Mountain Crest II and Better Therapeutics, Mountain Crest II has filed a registration statement on Form S-4 containing a proxy statement/prospectus (the “Form S-4”) with the Securities and Exchange Commission (the “SEC”). The Form S-4 includes a proxy statement to be distributed to holders of Mountain Crest II’s common stock in connection with Mountain Crest II’s solicitation of proxies for the vote by Mountain Crest II’s shareholders with respect to the proposed transaction and other matters as described in the Form S-4, as well as the prospectus relating to the offer of securities to be issued to Better Therapeutics’ stockholders in connection with the proposed business combination. After the Form S-4 has been declared effective, Mountain Crest II will mail a definitive proxy statement, when available, to its stockholders. Investors and security holders and other interested parties are urged to read the Form S-4, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about Mountain Crest II, Better Therapeutics, and the proposed business combination. Additionally, Mountain Crest II will file other relevant materials with the SEC in connection with the business combination. Copies of these documents may be obtained free of charge at the SEC’s web site at www.sec.gov. Securityholders of Mountain Crest II are urged to read the Form S-4 and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information.

Participants in the Solicitation

Mountain Crest II and its directors and executive officers may be deemed participants in the solicitation of proxies with respect to the proposed business combination under the rules of the SEC. Securityholders may obtain more detailed information regarding the names, affiliations, and interests of certain of Mountain Crest II’s executive officers and directors in the solicitation by reading Mountain Crest II’s Form S-4 and other relevant materials filed with the SEC in connection with the proposed business combination. Information about Mountain Crest II’s directors and executive officers and their ownership of Mountain Crest II common stock is set forth in Mountain Crest II’s annual report on Form 10-K for the year ended December 31, 2020, dated March 30, 2021, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of that filing. Other information regarding the interests of Mountain Crest II’s participants in the proxy solicitation, which in some cases, may be different than those of their stockholders generally, are set forth in the Form S-4 relating to the proposed business combination. These documents can be obtained free of charge at the SEC’s web site at www.sec.gov.

Better Therapeutics and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Mountain Crest II in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination are included in the Form S-4 for the proposed business combination.

Non-Solicitation

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the delivery of cognitive behavioral therapy and/ or prescription digital therapeutics or PDTs, by Better Therapeutics to address the root causes of type 2 diabetes and other cardiometabolic diseases; development of a proprietary platform and software-based solutions for treatment of type 2 diabetes, heart disease and other conditions; achievement of changes in neural pathways of the brain and lasting changes in behavior through cognitive behavioral therapy delivered by Better Therapeutics’ PDT; the capability of Better Therapeutics to address the underlying causes of certain diseases and its related potential to improve patient health while lowering healthcare costs; the potential for Better Therapeutics’ clinically validated mobile applications to be prescribed by physicians and reimbursed like traditional medicines; potential and significance of the results of the potentially pivotal study of BT-001 or any clinical or other trial or any expectations regarding the potentially pivotal trial of BT-001 to be fully enrolled in Q4 2021 with primary endpoint readout in Q1 2022; the potential success of BT-001 as a prescribed treatment used under physician supervision for people with uncontrolled type 2 diabetes; the possibility for the results of the potentially pivotal study to support a regulatory submission for marketing authorization from the FDA; the potential timing of Better Therapeutics’ expected progress towards developing and obtaining FDA approval for its products, including statements regarding the de novo submission to the FDA requesting marketing authorization following completion of any trial, pending positive outcomes, related research and validation studies; the clinical development of BT-002 and BT-003 in hypertension and hyperlipidemia and the potential timing of such development; the commencement of other pivotal studies and expected timing for the same; early clinical discovery in non-alcoholic fatty liver disease (NAFLD) and any expected timing of studies or trials for the same; the expected timing or start of any real-world evidence studies evaluating the long-term effectiveness and healthcare cost impact of BT-001; the potential impact of any studies announced with any study partners announced; the impact of any new patent filing or addition to intellectual property portfolio of Better Therapeutics; the future financial stability, strength or success of Better Therapeutics; the successful or positive impact that any financing transaction may have on Better Therapeutics’ business, including advancing Better Therapeutics’ pipeline of additional PDTs for other behavior-driven cardiometabolic diseases; statements as to the expected timing, completion and effects of the merger, any financing or debt transaction. In addition, any statements that refer to projections (including EBITDA, adjusted EBITDA, EBITDA margin and revenue projections), forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the FDA may not be satisfied with the design of any of Better Therapeutics’ studies and trials, and payers may not reimburse BT-001, if approved, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that the current COVID-19 pandemic will impact Better Therapeutics’ platform validation, product testing, the timing of the Better Therapeutics’ submission of the BT-001 for marketing approval from the FDA and other operations, and the risk that the Merger, any financing or debt transaction may not be completed in a timely manner or at all. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Better Therapeutics’ actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Mountain Crest II’s filings on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in Mountain Crest II and/or Better Therapeutics’ subsequent/future filings, if any, with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005295/en/

Better Therapeutics Media Contact

Heidi Chokeir, Ph.D.

[email protected]

+1 619 203 5391

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Mental Health Technology Medical Devices FDA Diabetes Fitness & Nutrition Clinical Trials Cardiology Software Health

MEDIA:

Logo

Legg Mason Partners Fund Advisor, LLC Announces Distributions for the Months of September, October, and November 2021

NEW YORK–(BUSINESS WIRE)–
Legg Mason Partners Fund Advisor, LLC announced today that Western Asset Diversified Income Fund (NYSE: WDI) has declared its distributions for the months of September, October, and November 2021.

The following dates apply to the distribution schedule below:

Month	Record Date	Ex-Dividend Date	Payable Date
September	9/23/2021	9/22/2021	10/1/2021
October	10/22/2021	10/21/2021	11/1/2021
November	11/22/2021	11/19/2021	12/1/2021

Ticker	Fund Name	Month		Amount				Type	Change from Previous Distribution
WDI	Western Asset Diversified Income Fund	September		$0.11700				Income	–
		October		$0.11700				Income
		November		$0.11700				Income

This press release is not for tax reporting purposes but is being provided to announce the amount of the Fund’s distributions that have been declared by the Board of Directors. In early 2022, after definitive information is available, the Fund will send shareholders a Form 1099-DIV, if applicable, specifying how the distributions paid by the Fund during the prior calendar year should be characterized for purposes of reporting the distributions on a shareholder’s tax return (e.g., ordinary income, long-term capital gain or return of capital).

Legg Mason Partners Fund Advisor, LLC, is an indirect, wholly-owned subsidiary of Franklin Resources, Inc. (“Franklin Resources”).

For more information about the Fund, please call 1-888-777-0102 or consult the Fund’s web site at www.lmcef.com. Hard copies of the Fund’s complete audited financial statements are available free of charge upon request.

Data and commentary provided in this press release are for informational purposes only. Franklin Resources and its affiliates do not engage in selling shares of the Fund.

Category: Distribution Related

Source: Franklin Resources, Inc.

Source: Legg Mason Closed End Funds

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005439/en/

Investor Contact: Fund Investor Services 1-888-777-0102

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Posted on September 9, 2021 8:03 am

Olympic Steel Names Cassandra Powers Vice President Human Resources

Olympic Steel Names Cassandra Powers Vice President Human Resources

CLEVELAND–(BUSINESS WIRE)–Olympic Steel Inc. (Nasdaq: ZEUS), a leading national metals service center, today announced that Cassandra (Cassy) Powers has been promoted to Vice President of Human Resources.

Ms. Powers’ promotion is part of a planned succession. She will succeed Ken F. Sloan, who has announced his plan to retire in 2022. In her new role, Ms. Powers will report directly to Richard T. Marabito, Olympic Steel’s Chief Executive Officer, and lead the Company’s strategic employee acquisition, engagement, development and retention efforts.

“Cassy is a positive, energetic advocate for our employees and a valued member of, and partner for, our leadership team,” said Mr. Marabito. “She is an outstanding role model for our Core Values, a champion for our continued diversity, equity and inclusion work, and brings a clear strategic vision for the future of our talent management efforts.”

Ms. Powers joined Olympic Steel’s Human Resources team in 2016, bringing with her more than 11 years of human resources and talent acquisition experience. Throughout her tenure, she has earned roles of increasing responsibility, including leading the Company’s recruitment efforts as Talent Acquisition Manager and, most recently, supporting strategic talent management as Regional Human Resources Manager.

Ms. Powers earned her bachelor’s degree in business and organizational communication from the University of Akron. She is a Society for Human Resources Management Certified Professional (SHRM-CP) and serves on the Metals Service Center Institute (MSCI) Diversity, Equity and Inclusion (DEI) Task Force.

About Olympic Steel

Founded in 1954, Olympic Steel is a leading U.S. metals service center focused on the direct sale of processed carbon, coated and stainless flat-rolled sheet, coil and plate steel, aluminum, tin plate, and metal-intensive branded products. The Company’s CTI subsidiary is a leading distributor of steel tubing, bar, pipe, valves and fittings, and fabricator of value-added parts and components. Headquartered in Cleveland, Ohio, Olympic Steel operates from 35 facilities in North America.

For additional information, please visit the Company’s website at www.olysteel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005525/en/

Michelle Pearson-Casey

Vice President Corporate Communications & Marketing

(216) 292-3800

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Steel Manufacturing

MEDIA:

Logo

Vantage Data Centers Enters Asia-Pacific Region with Launch of Five Markets Through Acquisitions of Agile Data Centers and PCCW’s Data Center Business

APAC expansion fueled by $1.5B in incremental equity raise led by DigitalBridge

DENVER–(BUSINESS WIRE)–
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its expansion into the Asia-Pacific market through two acquisitions. DigitalBridge Investment Management, the company’s major stakeholder, along with participation from other existing Vantage investors, contributed an additional $1.5 billion in equity capital. Following the closing of both transactions, Vantage will offer data center services across Tokyo, Osaka, Melbourne, Hong Kong and Kuala Lumpur to hyperscale, cloud and large enterprise customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005500/en/

Vantage’s APAC expansion is anchored by two acquisitions. First, Vantage has acquired Agile Data Centers, a data center provider in the Asia-Pacific region developing greenfield hyperscale campuses totaling 168MW of critical IT load in Tokyo, Osaka and Melbourne. Second, the data center portfolio of PCCW Ltd. (PCCW DC), which DigitalBridge previously announced plans to acquire, will become part of Vantage upon the transaction closing. Closing is expected in the fourth quarter of 2021 subject to customary closing conditions. PCCW DC is one of the region’s leading data center businesses with approximately 100MW of existing and expansion critical IT load across multiple facilities in Hong Kong and Kuala Lumpur.

Giles Proctor, formerly president and co-founder of Agile Data Centers, now serves as president of Vantage’s APAC business, overseeing a team that will include nearly 150 employees upon closing of the PCCW DC transaction. Brian Groen, senior vice president of data centers, PCCW DC, will join Vantage as senior vice president, APAC, upon closing.

“Following successful expansions throughout the United States, Canada and Europe over the past three years, we are expanding to Asia Pacific to better serve customers on a global basis. The key to our global expansion has been finding well-aligned partners who bring local expertise, an established footprint, a strong management team and the ability to scale quickly,” said Sureel Choksi, president and CEO, Vantage Data Centers. “The combination of Agile and PCCW’s data center business does just that, and I’m thrilled to welcome Giles Proctor, Brian Groen and their highly talented teams to Vantage.”

“As we continue building a global digital infrastructure platform, we recognized a strategic opportunity to combine the market penetration, expertise and strength of two valuable portfolio companies, Vantage and Agile, with the established foothold of PCCW DC to serve customers in this high growth region,” said Jon Mauck, senior managing director of DigitalBridge Investment Management. “The Vantage team has proven across North America and Europe that it is highly skilled at taking full advantage of both acquisitions and greenfield opportunities to quickly become a leading provider in new markets.”

“My team and I are excited to join the global Vantage family to expand the combined company’s presence in Asia Pacific,” said Proctor. “This offers our customers additional key markets in which to do business with trusted partners who bring in-country knowledge and a commitment to building and operating high quality, sustainably designed data center facilities.”

More information on Vantage’s current global campuses can be found at https://vantage-dc.com/data-center-locations/.

About Vantage Data Centers

Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating in North America, Europe and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.

For more information, visit www.vantage-dc.com.

About DigitalBridge

DigitalBridge Group, Inc. (NYSE: DBRG) is a leading global digital infrastructure REIT. With a heritage of over 25 years of investing in and operating businesses across the digital ecosystem including cell towers, data centers, fiber, small cells and edge infrastructure, the DigitalBridge team manages a $35 billion portfolio of digital infrastructure assets on behalf of its limited partners and shareholders. DigitalBridge is headquartered in Boca Raton with key offices in Los Angeles, New York, London and Singapore.

For more information, visit www.digitalbridge.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005500/en/

Press Contacts

Vantage Data Centers

Mark Freeman

Vantage Data Centers

[email protected]

+1 202-680-4243

Robin Bectel

REQ for Vantage Data Centers

[email protected]

+1 703-287-7827

DigitalBridge

Severin White

Managing Director, Head of Public Investor Relations

[email protected]

+1 212-547-2777

Joele Frank, Wilkinson Brimmer Katcher

Julie Hamilton / Jon Keehner

[email protected]

+1 212-355-4449

KEYWORDS: Colorado United States North America Asia Pacific

INDUSTRY KEYWORDS: Data Management Technology Commercial Building & Real Estate Construction & Property Building Systems Hardware Landscape

MEDIA:

Logo

Photo

Vantage Data Centers’ future Melbourne campus will include 48MW of critical IT load across three facilities. (Photo: Business Wire)

Dynatrace Software Intelligence Platform Available on Microsoft Azure

Native SaaS on Microsoft Azure provides customers with easy access to complete observability and advanced AIOps for Azure as well as multicloud environments

WALTHAM, Mass.–(BUSINESS WIRE)–
Dynatrace and Microsoft announced today they have expanded their strategic collaboration to help the world’s leading organizations accelerate innovation and tame cloud complexity. As part of this, the Dynatrace® Software Intelligence Platform will be available as native SaaS on Microsoft Azure, providing customers increased flexibility and choice when selecting cloud service providers. In addition, the Dynatrace platform will be available natively in the Microsoft Azure Portal, making Dynatrace setup automatic while also streamlining procurement and simplifying the user experience. These enhancements make it easier than ever for Dynatrace’s and Microsoft’s joint customers to leverage Dynatrace’s deep cloud observability, advanced AIOps, and continuous runtime application security capabilities in Microsoft Azure and multicloud environments.

“Dynatrace and Azure have transformed the way we work by helping us drive digital innovation at the speed our business requires,” said Mark Forrester, Digital Readiness Manager at Mitchells & Butlers. “Dynatrace’s deep observability and advanced AIOps enable our developers to ensure only the highest quality code makes it to production without manual checks or intervention, which accelerates our delivery of new digital services for our customers.”

“We are delighted that the Dynatrace Software Intelligence Platform will be available on Microsoft Azure so customers can intelligently monitor and manage their Azure and multicloud workloads, automate manual processes, accelerate cloud adoption, and benefit from modernization initiatives,” said Casey McGee, Vice President, Global ISV Sales, Microsoft. “In addition, making Dynatrace available natively in the Azure portal and available in the Azure Marketplace will make it easy for customers to find and realize the benefits of this powerful solution.”

Dynatrace’s native presence in the Azure Portal enables customers to:

• Procure and deploy the Dynatrace® platform with just a few clicks and consolidate billing through the Azure Marketplace.
• Easily send Azure logs and metrics to Dynatrace, adding to Dynatrace distributed tracing and code-level analysis for complete observability.
• View and manage Azure resources monitored by Dynatrace.
• Automatically receive Dynatrace software updates.
• Access the Dynatrace platform with Single Sign-On using Azure credentials.

“Microsoft is a critical partner, and we share a goal to empower the world’s largest organizations to accelerate their digital transformation initiatives,” said Mike Maciag, Chief Marketing Officer at Dynatrace. “Delivering the Dynatrace platform as native SaaS on Microsoft Azure makes it easy for more organizations to leverage Dynatrace’s industry-leading observability, AIOps, and application security to tame the most complex cloud environments, reduce risk and manual effort, and drive more innovation.”

Dynatrace SaaS on Microsoft Azure will be generally available within 90 days. Dynatrace on the Azure portal will be available for early access customers within 90 days, with general availability coming soon. To learn more, visit the Dynatrace blog or the Dynatrace on Azure solution landing page. For additional details on the partnership, read the Microsoft story about Dynatrace.

About Dynatrace

Dynatrace provides software intelligence to simplify cloud complexity and accelerate digital transformation. With automatic and intelligent observability at scale, our all-in-one platform delivers precise answers about the performance and security of applications, the underlying infrastructure, and the experience of all users to enable organizations to innovate faster, collaborate more efficiently, and deliver more value with dramatically less effort. That’s why many of the world’s largest enterprises trust Dynatrace® to modernize and automate cloud operations, release better software faster, and deliver unrivalled digital experiences.

Curious to see how you can simplify your cloud? Let us show you. Visit our trial page for a free 15-day Dynatrace trial.

To learn more about how Dynatrace can help your business, visit www.dynatrace.com, visit our blog and follow us on Twitter @dynatrace.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005514/en/

Meg Brenner

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

Posted on September 9, 2021 8:03 am

Genius Sports Agrees to Major Partnership With Penn Interactive to Power its Barstool Sportsbook With Official Data and Fan Engagement Solutions

Genius Sports Agrees to Major Partnership With Penn Interactive to Power its Barstool Sportsbook With Official Data and Fan Engagement Solutions

• Genius Sports to power Barstool Sportsbook with full suite of U.S. sports content, including exclusive EPL, NASCAR, and NFL sports data feeds and dynamic content solutions

PHILADELPHIA, & LONDON–(BUSINESS WIRE)–
Genius Sports Limited (NYSE: GENI) (“Genius Sports”) the official data, technology and commercial partner that powers the ecosystem connecting sports, betting and media, has entered into a long-term partnership with Penn Interactive (“Penn Interactive” or the “Company”) to provide official data and fan engagement solutions for the Company’s Barstool Sportsbook.

Penn Interactive currently operates online Barstool Sportsbooks across nine U.S. states, including Pennsylvania, Michigan, Illinois and New Jersey. Genius Sports will provide Barstool Sportsbook with its market-leading official data, including access to select official sports data from the U.S. and international sports leagues.

Across player acquisition, engagement and long-term retention, Barstool Sportsbook has also partnered with Genius Sports for its marketing and engagement strategy.

The agreement makes Barstool Sportsbook the latest U.S. sports betting brand to adopt Genius Sports’ exclusive official sports content, which includes NASCAR’s full suite of official data-powered in-race betting markets, launched in partnership with Genius Sports in 2020, as well as access to the NFL’s real-time statistics, proprietary Next Gen Stats (“NGS”) and official sports betting data feed. Genius Sports will also provide Barstool Sportsbook with its global official sports data portfolio from other top tier leagues, including the English Premier League, Liga MX, Argentine and Colombian soccer.

“We are excited to be partnering with Genius Sports for official data beginning with tonight’s kickoff,” said Jon Kaplowitz, Head of Penn Interactive. “Delivering official data to our growing, loyal audience will provide tremendous wagering opportunities for our users. We also look forward to reaching sports fans who may not yet have experienced the Barstool Sportsbook through access to marketing inventory on NFL digital properties from Genius Sports.”

“Our partnership with Penn Interactive will provide one of the fastest-growing and most innovative sports betting brands with unique content across the whole player experience,” said Mark Locke, CEO at Genius Sports. “Barstool Sports is uniquely positioned in the U.S. market, appealing to a dynamic and passionate fan base. With Genius’ official sports data, next-generation marketing and fan engagement solutions, we look forward to supporting Barstool Sportsbook’s U.S. expansion.”

ENDS

Contacts

About Genius Sports

Genius Sports is the official data, technology and commercial partner that powers the global ecosystem connecting sports, betting and media. We are a global leader in digital sports content, technology and integrity services. Our technology is used in over 150 countries worldwide, empowering sports to capture, manage and distribute their live data and video, driving their digital transformation and enhancing their relationships with fans.

We are the trusted partner to over 400 sports organizations globally, including many of the world’s largest leagues and federations such as the NFL, EPL, FIBA, NCAA, NASCAR, AFA and PGA.

Genius Sports is uniquely placed through cutting-edge technology, scale and global reach to support our partners. We are more than just a technology company, we build long-term relationships with sports at all levels, helping them to control and maximize the value of their content while providing technical expertise and round-the-clock support.

About Penn Interactive

Penn Interactive, the wholly owned interactive division of Penn National Gaming, Inc., operates retail sports betting across the Company’s portfolio, as well online social casino, bingo, and iCasino products. In February 2020, Penn National entered into a strategic partnership with Barstool Sports, whereby Barstool is exclusively promoting the Company’s land-based and online casinos and sports betting products, including the Barstool Sportsbook mobile app, to its national audience.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005522/en/

Press:

Chris Dougan, Chief Communications Officer

Genius Sports

+1 (202) 766-4430

[email protected]

Tristan Peniston-Bird / Charlie Harrison, The One Nine Three Group

+44 7772 031 886 / +44 7884 136 143

[email protected] / [email protected]

Eric Schippers

Sr. Vice President, Public Affairs & Government Relations

[email protected]

Investors:

Brandon Bukstel, Investor Relations Manager

Genius Sports

+1 (954) 554-7932

[email protected]

KEYWORDS: Pennsylvania Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Data Management Entertainment Sports Technology Other Sports Software Casino/Gaming

MEDIA:

Logo

Embark to Host Embark Day on September 22 Ahead of Nasdaq Listing

SAN FRANCISCO–(BUSINESS WIRE)–Embark Trucks (“Embark” or “the company”), a leading developer of self-driving software for the trucking industry, today announced it will host Embark Day on September 22, 2021 at its San Francisco headquarters. Embark Day will bring together a variety of constituents including investors, media, and equity research analysts for a deep dive into the company’s technology, business, and strategy. Embark Day will take place ahead of the company’s planned listing on Nasdaq, following the completion of its previously announced business combination with Northern Genesis Acquisition Corp. II (NYSE: NGAB) (“Northern Genesis 2”).

At the investor-focused event, members of Embark’s leadership team – including co-founder and CEO Alex Rodrigues and CFO Richard Hawwa – will provide attendees with an update on Embark since the announcement of the definitive business combination agreement with Northern Genesis 2 on June 23, 2021, as well as feature additional members of the Embark team during the following sessions:

• An Open House with the Embark Team, including co-founder and CTO Brandon Moak and other industry-leading experts in Engineering, Operations, Partnerships, and Policy
• The opportunity to experience Embark’s technology first-hand and ride in an Embark-equipped self-driving truck at Embark’s Oakland Transfer Point site
• A detailed business update from CEO Alex Rodrigues and CFO Richard Hawwa
• An in-depth look at Embark’s differentiated go-to market partnership strategy
• Insight from existing Embark investor and Partner and Head of Growth at Sequoia Capital, Pat Grady
• A fireside chat with the Honorable Elaine Chao, Former U.S. Secretary of Transportation and Labor
• More exciting developments to be announced on Embark Day

Please email [email protected] if you are interested in attending or learning more.

About Embark

​​Embark is an autonomous vehicle company building the software powering autonomous trucks, focused on improving the safety, efficiency, and sustainability of the nearly $700 billion a year trucking market. Headquartered in San Francisco, CA since its founding in 2016, Embark is America’s longest-running self-driving truck program. The company partners with some of the largest shippers and carriers in the nation, collectively representing over 30,000 trucks.

Embark’s mission is to realize a world where consumers pay less for the things they need, drivers stay close to the homes they cherish, and roads are safer for the people we love. To learn more about Embark, visit embarktrucks.com.

About Northern Genesis 2

Northern Genesis 2 is a special purpose acquisition company formed for the purpose of effecting a merger, stock exchange, acquisition, reorganization or similar business combination with one or more businesses. The management team overseeing the Northern Genesis 2 investment platform brings a unique entrepreneurial owner-operator mindset and a proven history of creating shareholder value across the sustainable power and energy value chain. The team is committed to helping the next great public company find its path to success; a path which will most certainly recognize the growing sensitivity of customers, employees and investors to alignment with the principles underlying sustainability.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Embark’s and Northern Genesis 2’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Embark’s and Northern Genesis 2’s expectations with respect to future performance. These forward-looking statements also involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted in connection with any proposed business combination; (2) the inability to complete any proposed business combination in a timely manner or at all; (3) delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals or complete regulatory reviews required to complete any proposed business combination; (4) the risk that the business combination may not be completed by Northern Genesis 2 business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought; (5) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the stockholders of Northern Genesis 2 and Embark and the satisfaction of the minimum trust account amount following redemptions by Northern Genesis 2’s public stockholders; (6) the lack of a third party valuation in determining whether or not to pursue the proposed business combination; (7) the risk that any proposed business combination disrupts current plans and operations and/or the impact that the announcement of the proposed business combination may have on Embark’s business relationships; (8) the inability to recognize the anticipated benefits of any proposed business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain key employees; (9) costs related to the any proposed business combination; (10) changes in the applicable laws or regulations; (11) volatility in the price of Northern Genesis 2’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Embark plans to operate, variations in performance across competitors, changes in laws and regulations affecting Embark’s business and changes in the combined capital structure; (12) the possibility that Embark or Northern Genesis 2 may be adversely affected by other economic, business, and/or competitive factors; (13) the impact of the global COVID-19 pandemic; and (14) other risks and uncertainties separately provided to you and indicated from time to time described in filings and potential filings by Embark and Northern Genesis 2 with the U.S. Securities and Exchange Commission (the “SEC”), including those discussed in Northern Genesis 2’s Annual Report Form 10-K for the fiscal year ended December 31, 2020 (“Form 10-K”) and Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and those that are expected to be included in the registration statement on Form S-4 and proxy statement/prospectus discussed below and other documents filed by Northern Genesis 2 from time to time. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Embark and Northern Genesis 2 caution that the foregoing list of factors is not exhaustive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Embark and Northern Genesis 2 undertake no obligation to and accept no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Additional Information About the Proposed Transactions and Where to Find It

The proposed transactions will be submitted to stockholders of Northern Genesis 2 for their consideration. Northern Genesis 2 has filed a registration statement on Form S-4 (the “Registration Statement”) with the SEC which includes a preliminary proxy statement to be distributed to Northern Genesis 2’s stockholders in connection with Northern Genesis 2’s solicitation for proxies for the vote by Northern Genesis 2’s stockholders in connection with the proposed transactions and other matters as described in the Registration Statement, as well as the preliminary prospectus relating to the offer of the securities to be issued to Embark’s shareholders in connection with the completion of the proposed merger. After the Registration Statement has been declared effective, Northern Genesis 2 will mail a definitive proxy statement and other relevant documents to its stockholders as of the record date established for voting on the proposed transactions. Northern Genesis 2’s stockholders and other interested persons are advised to read the preliminary proxy statement/prospectus and any amendments thereto and, once available, the definitive proxy statement/prospectus, in connection with Northern Genesis 2’s solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the proposed business combination, because these documents will contain important information about Northern Genesis 2, Embark and the proposed business combination. Stockholders may also obtain a copy of the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC regarding the proposed transactions and other documents filed with the SEC by Northern Genesis 2, without charge, at the SEC’s website located at www.sec.gov or by directing a request to Northern Genesis 2.

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

Participants in the Solicitation

Northern Genesis 2, Embark and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from Northern Genesis 2’s stockholders in connection with the proposed transactions. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Northern Genesis 2’s stockholders in connection with the proposed transactions will be set forth in Northern Genesis 2’s proxy statement/prospectus when it is filed with the SEC. You can find more information about Northern Genesis 2’s directors and executive officers in Northern Genesis 2’s Form 10-K and Forms 10-Q filed with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Stockholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005289/en/

Embark Trucks, Inc.

Investor Relations:

[email protected]

Media:

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Fleet Management Software Automotive Trucking Technology Logistics/Supply Chain Management General Automotive Transport

MEDIA:

Logo

Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Executive Director, Biotech Equity Research for Oppenheimer & Co. at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 9:55 a.m. ET.

A live webcast of the conversation will be available on the Investors & Media page of the company’s website. The event will remain archived on the website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005214/en/

Corporate Contact:

Joshua Reed

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

[email protected]

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Optical Health

MEDIA:

Logo

The RMR Group Appoints Andrew Fay Senior Vice President

$32 Billion Alternative Asset Manager Enhances Capability to Source Private Capital for Investments in Core Real Estate

Financial Industry Veteran Brings 30 Years of Experience to RMR

NEWTON, Mass.–(BUSINESS WIRE)–The RMR Group Inc. (Nasdaq: RMR) today announced the appointment of Andrew Fay as Senior Vice President. In this new role, Mr. Fay will be responsible for establishing and developing a capital markets team that will focus on sourcing capital from private investment partners including ultra-high net worth investors, family offices, targeted registered investment advisors, foundations and endowments.

Adam Portnoy, President & Chief Executive Officer, made the following statement:

“We welcome Andy to RMR’s senior leadership team and look forward to utilizing his multi-decade experience in the capital markets and wealth management industries and his ability to build relationships with ultra-high net worth investors, family offices and institutions. We believe that RMR’s strong historical track record and expertise in managing a diverse, nationwide portfolio of core real estate assets will appeal to new audiences and will complement the traction we have already established with investments from sovereign wealth funds.”

The creation of this new role builds on RMR’s effort to expand its capital sources into private markets and so far has resulted in nearly $1 billion of new investment, primarily from sovereign wealth funds. This capital includes investments in, most notably, the $680 million joint venture RMR client Industrial Logistics Properties Trust (Nasdaq: ILPT) entered into for 12 mainland U.S. industrial assets.

Mr. Fay has more than 30 years of experience in financial services and expertise in both the institutional and private client marketplace. He most recently served as Head of Family Office Services for Fidelity Investments, where he played a central role in creating the company’s first ultra-high net worth and family office business. Previously, he held roles at Bank Boston and FleetBoston Securities Corp. as well as Manufacturers Hanover Trust. Mr. Fay is an advisory board member of the UNWH Institute. He earned his Bachelor’s degree in Government and French with a minor in Economics from Bowdoin College and is a certified investment management analyst.

About The RMR Group

The RMR Group Inc. (Nasdaq: RMR) is a holding company and substantially all of its business is conducted by its majority owned subsidiary, The RMR Group LLC, or RMR. RMR is a leading U.S. alternative asset management company, unique for its focus on commercial real estate (CRE) and related businesses. RMR’s vertical integration is supported by its more than 600 real estate professionals in over 30 offices nationwide who manage over $32 billion in assets under management and leverage 35 years of institutional experience in buying, selling, financing and operating CRE. RMR benefits from a scalable platform, a deep and experienced management team and a diversity of direct real estate strategies across its clients. RMR is headquartered in Newton, MA and was founded in 1986. For more information, please visit www.rmrgroup.com.

WARNING REGARDING FORWARD LOOKING STATEMENTS

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon RMR’s present beliefs and expectations, but these statements and the implications of these statements are not guaranteed to occur and may not occur for various reasons, some of which are beyond RMR’s control. For example:

• The appointment of Mr. Fay and the enumeration of his qualifications may imply that RMR’s business and operations will improve as a result of his appointment. However, RMR’s business and operations are subject to various risks, many of which are beyond its control. As a result, RMR’s business and operations may not improve despite the appointment of Mr. Fay.
• Mr. Portnoy states that RMR looks forward to utilizing Mr. Fay’s experience in the capital markets and wealth management industries and his ability to build relationships with ultra-high net worth investors, family offices and institutions and believes that RMR’s strong historical track record and expertise in managing a diverse, nationwide portfolio of core real estate assets will appeal to new audiences. There can be no assurance, however, that the appointment of Mr. Fay will enhance RMR’s ability to source private capital or provide any benefit to RMR’s shareholders or client companies.

For these reasons, among others, investors are cautioned not to place undue reliance upon any forward looking statements in this press release. Except as required by law, RMR does not intend to update or change any forward looking statements as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005182/en/

Christopher Ranjitkar

Senior Director, Marketing & Corporate Communications

(617) 219-1473

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo